These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27244829)

  • 1. FDA Approval of Extended-Release Oxycodone for Children With Severe Pain.
    Yang YT; Chen B; Bennett CL
    Pediatrics; 2016 May; 137(5):. PubMed ID: 27244829
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA approves oxycodone and acetaminophen extended-release tablets.
    J Pain Palliat Care Pharmacother; 2014 Jun; 28(2):188-9. PubMed ID: 25011144
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD).
    Fleming AB; Carlson DR; Varanasi RK; Grima M; Mayock SP; Saim S; Kopecky EA
    Pain Pract; 2016 Mar; 16(3):334-44. PubMed ID: 25639548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic pain, addiction, and Zohydro.
    Olsen Y; Sharfstein JM
    N Engl J Med; 2014 May; 370(22):2061-3. PubMed ID: 24758596
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term efficacy, safety and tolerability of Remoxy for the management of chronic pain.
    Pergolizzi JV; Zampogna G; Taylor R; Raffa RB
    Expert Rev Neurother; 2015 Mar; 15(3):231-8. PubMed ID: 25683255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the tamper-resistant properties of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
    Eisenhauer TD; Matchett M; Heasley R; Morton T; Devarakonda K; Giuliani M; Young JL; Barrett T
    Drug Dev Ind Pharm; 2016 Jan; 42(1):157-165. PubMed ID: 26146769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA chief defends Zohydro approval as US states rebel.
    McCarthy M
    BMJ; 2014 Apr; 348():g2939. PubMed ID: 24764572
    [No Abstract]   [Full Text] [Related]  

  • 9. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
    Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Rossiter LF; Michna E
    Pain Med; 2014 Sep; 15(9):1450-4. PubMed ID: 25041231
    [No Abstract]   [Full Text] [Related]  

  • 10. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
    Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
    Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
    Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
    J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxycodone extended release capsules for the treatment of chronic pain.
    Mercadante S
    Expert Rev Neurother; 2017 May; 17(5):427-431. PubMed ID: 28277802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developments in managing severe chronic pain: role of oxycodone-naloxone extended release.
    Fanelli G; Fanelli A
    Drug Des Devel Ther; 2015; 9():3811-6. PubMed ID: 26229442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA actions to prevent prescription drug abuse.
    Jeske AH
    Tex Dent J; 2005 Jul; 122(7):634-45. PubMed ID: 16152888
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain.
    Friedmann N; Klutzaritz V; Webster L
    Pain Med; 2011 May; 12(5):755-60. PubMed ID: 21481168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA panel debates merits of next-generation opioid formulations.
    Lavine G
    Am J Health Syst Pharm; 2009 Jan; 66(1):8-11. PubMed ID: 19106336
    [No Abstract]   [Full Text] [Related]  

  • 17. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs.
    Cicero TJ; Ellis MS; Kasper ZA
    Pain; 2016 Jun; 157(6):1232-1238. PubMed ID: 27186712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approval of New Opioid Raises Concerns.
    Aschenbrenner DS
    Am J Nurs; 2019 Feb; 119(2):20-21. PubMed ID: 30681473
    [No Abstract]   [Full Text] [Related]  

  • 19. A new abuse-deterrent opioid--Xtampza ER.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):77-8. PubMed ID: 27305067
    [No Abstract]   [Full Text] [Related]  

  • 20. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
    Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
    J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.